Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 8/20 | 0.39 |
| ▸ | F10 | P00742 | 15/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 11/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623653 | 0.93 | F10 (0.43) | PLAUF2F10PRSS1ACACB | |
| SCHEMBL1625141 | 0.93 | F10 (0.43) | PLAUF2F10PRSS1ACACB | |
| SCHEMBL1622580 | 0.90 | PLAU (0.39) | PLAUF2F10PRSS1ACACB | |
| SCHEMBL1623850 | 0.86 | PLAU (0.41) | PLAUF2F10PRSS1 | |
| SCHEMBL1624776 | 0.83 | PLAU (0.40) | PLAUF2F10PRSS1 | |
| SCHEMBL1624252 | 0.83 | PLAU (0.40) | PLAUF2F10PRSS1 | |
| SCHEMBL1624814 | 0.83 | F2 (0.39) | PLAUF2F10PRSS1 | |
| SCHEMBL1623526 | 0.83 | F2 (0.39) | PLAUF2F10PRSS1 | |
| SCHEMBL1624957 | 0.82 | F10 (0.47) | PLAUF2F10PRSS1 | |
| SCHEMBL1624474 | 0.82 | F10 (0.47) | PLAUF2F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928137-B2 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2011-04-19 | — | — | US | disclosed |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | LIEBESCHUETZ JOHN W | 2007-07-05 | — | — | US | disclosed |
| US-7220781-B2 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2007-05-22 | — | — | US | disclosed |
| EP-1009758-B1 | META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-20040143018-A1 | Meta-benzamidine derivatives as serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| US-6740682-B2 | TREATMENT OF THROMBOTIC DISEASES, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY. | TULARIK LIMITED (GB) | 2004-05-25 | — | — | US | disclosed |
| US-20020055522-A1 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2002-05-09 | — | — | US | disclosed |
| EP-1009758-A1 | META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | Protherics Molecular Design Limited (GB) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999011658-A1 | META-BENZAMIDINE DERIVATIVES AS SERIN PROTEASE INHIBITORS | PROTEUS MOLECULAR DESIGN LTD. (GB) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055522-A1 | Meta-benzamidine derivatives as serine protease inhibitors | SERPINE1, PEPD, PRSS1 | PLAU 87/4885F2 113/4885F10 378/4885 |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | PEPD, SERPINE1, HPN | PLAU 90/4885F2 103/4885F10 292/4885 |
| US-20040143018-A1 | Meta-benzamidine derivatives as serine protease inhibitors | SERPINE1, PEPD, PRSS1 | PLAU 87/4885F2 113/4885F10 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.